Overview

A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group

Status:
Completed

Trial end date:
2007-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the safety and tolerability of GT4P administered orally as a single dose, and twice daily for 7 consecutive days, to subjects with hepatic impairment with cirrhosis (Child-Pugh scores of A, B, or C) and to a gender matched and similar age control group with normal hepatic function.

Phase:

Phase 1

Details

Lead Sponsor:

Horizon Pharma Ireland, Ltd., Dublin Ireland

Collaborator:

Ucyclyd Pharma, Inc.

Treatments:

4-phenylbutyric acid